NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Buparlisib (Primary) ; Paclitaxel; Trastuzumab
- Indications Early breast cancer
- Focus Therapeutic Use
- Acronyms NeoPHOEBE
- Sponsors Novare Pharmaceuticals; Novartis Pharmaceuticals
- 04 Feb 2019 Austria, Belgium, Brazil, France, Italy, New Zealand, Peru, Switzerland, Taiwan, United Kingdom were planned locations according European Clinical Trials Database.
- 15 Sep 2017 Primary endpoint has not been met. (Pathological complete response (pCR) rate) as per results published in the European Journal of Cancer
- 15 Sep 2017 Results published in the European Journal of Cancer